Efficacy of Quetiapine in Parkinson's Psychosis

Completed

• Conditions: Parkinson's disease; Nervous System Diseases

• Registration Number: ISRCTN74681449
• Lead Sponsor: King's College London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-09
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria

Exclusion Criteria

1. Anti-psychotic medication in the preceding 3 months
2. Any contra-indication to quetiapine
3. Any important drug interactions
4. Major concomitant medical illness
5. History of uncontrolled diabetes or hypertension
6. Changes in medication in the last 14 days

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Improvment in psychotic symptoms<br>2. Parkinsonian symptoms<br>3. Depressive symptoms<br>4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen)

Secondary Outcome Measures

Name	Time	Method
1. Activities of daily living<br>2. Cognitive function <br>3. Carer burden